SummaryRMgm-5268
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 36403748 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Yuda M, Nishi T |
Name Group/Department | Department of Medical Zoology |
Name Institute | Mie University School of Medicine |
City | Mie, Tsu |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5268 |
Principal name | P52/SPECT2 DKO parasites |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | From analysis of B9(-) parasites (Rmgm-5266) that have the same phenotype as P52(-) parasites: Normal numbers of motile salivary gland sporozoites are formed. While 30 wild-type sporozoites were sufficient to establish infection in all rats, Even 1 × 10 B9(-) sporozoites were insufficient to establish infection in all rats. |
Liver stage | From analysis of B9(-) parasites (Rmgm-5266) that have the same phenotype as P52(-) parasites: B9(-) parasites formed abnormal liver stages (LS) and displayed increased cell traversal activity. The number of B9(-) LS parasites formed in HepG2 cells was 6% that of wild-type parasites at 24 and 48 h post-inoculation (hpi) of sporozoites. The average diameter of the B9(-) LS parasites decreased to approximately 80 % that of wild-type LSs at 48 hpi. There was a decreased number of sporozoites entering the hepatocytes by productive invasion and reciprocally, an increased number of sporozoites that continued migration through the hepatocytes. Evidence is presented that B9(-) LS parasites develop in the nucleus of hepatocytes. From analysis of B9/SPECT2 DKO parasites (RMgm-5267) that have the same phenotype as P52/SPECT2 DKO parasites: With t he disruption of SPECT2 in B9(-) parasites, the cell traversal activity of sporozoites disappeared. In HepG2 cell culture no LSs of B9/SPECT2 DKO parasites were identified using fluorescence microscopy, demonstrating that all LS parasites inside the nucleus 5 were derived from sporozoites that invaded Hep G2 cells for cell traversal. Sporozoites in side these cells were still observed in B9 SPECT 2 DKO parasites and the number increased following SPECT2 disruption to a level similar to that of wild type. This result means that sporozoites lacking both cell invasion modes still enter ed HepG2 cells. |
Additional remarks phenotype | Mutant/mutation Protein (function) The spect2/pplp1 gene is a member of a small, conserved family of proteins encoding perforin-like proteins containing membrane-attack complex/perforin domains (MACPF). The P. berghei genome contains 5 PLP proteins. SPECT2/PPLP1 is specifically expressed in salivary gland sporozoites (not in midgut sporozoites) and has a micronemal location (micronemes) Additional information From the paper analysing B9(-) parasites (RMgm-5266): We also performed cell wounding and membrane repair assays to evaluate the cell traversal activity of B9(-) sporozoites . The number of HepG2 cells damaged by invasion of B9(-) sporozoites was approximately 3 fold higher than that of wild type parasites. These results suggest that the disruption of B9 impaired the switching capacity of sporozoites . More specifically, there was a decreased number of sporozoites entering the hepatocytes by productive invasion and reciprocally, an increased number of sporozoites that continued migration through the hepatocytes . This phenotype of B9(-). is similar to the previously reported phenotypes of P52 disrupted P52(-) and P36 disrupted P36(-) parasites |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1002200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0404500 | ||||||||||||||||||||||||
Gene product | 6-cysteine protein P52 | ||||||||||||||||||||||||
Gene product: Alternative name | P36p; Pb36p; P52 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||||||||
Promoter of the selectable marker | unknown | ||||||||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | P52(-)GFP parasites were generated by insertion of a GFP expression cassette into the B9 gene locus of wild-type parasites by homologous recombination. P52(-)GFP parasites were sorted using flow cytometry. The selected parasites were further separated from wild-type parasites by limiting dilution. Double knockout parasites were prepared from these parasites by additional disruption of SPECT2 using a pyrimethamine-resistant gene as a selectable marker. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1006300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0408700 | ||||||||||||||||||||||||
Gene product | perforin-like protein 1 | sporozoite micronemal protein essential for cell traversal | ||||||||||||||||||||||||
Gene product: Alternative name | PLP1; PPLP1, SPECT2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | DD | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | pbdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | P52(-)GFP parasites were generated by insertion of a GFP expression cassette into the B9 gene locus of wild-type parasites by homologous recombination. P52(-)GFP parasites were sorted using flow cytometry. The selected parasites were further separated from wild-type parasites by limiting dilution. Double knockout parasites were prepared from these parasites by additional disruption of SPECT2 using a pyrimethamine-resistant gene as a selectable marker. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |